secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001847903-24-000126
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q2 net loss widens to $43.8M; cash $294.8M; ORX750 data expected 2H 2024
--------------------------------------------------------------------------------

- Net loss $43.8M vs $24.9M YoY; prior Q2 included $24.1M tax benefit.
- Cash $294.8M; funds operations into mid-2026; raised $107.3M net in public offering.
- ORX750 Phase 1 initiated; PoC data in sleep-deprived volunteers expected 2H 2024 using MWT.
- ORX142 nominated as development candidate; IND-enabling activities underway.
- SerpinPC registrational program progressing; PRESent-2 Part 1 interim analysis planned 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000126/0001847903-24-000126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790324000126/cnta-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001847903-24-000126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer